This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Halozyme Therapeutics (HALO) Moves 7.3% Higher: Will This Strength Last?
by Zacks Equity Research
Halozyme Therapeutics (HALO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
AnaptysBio, Inc. (ANAB) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
AnaptysBio, Inc. (ANAB) delivered earnings and revenue surprises of -50.57% and 87.99%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
AnaptysBio, Inc. (ANAB) Soars 6.2%: Is Further Upside Left in the Stock?
by Zacks Equity Research
AnaptysBio, Inc. (ANAB) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
AnaptysBio's (ANAB) Acne Study on Imsidolimab Fails to Meet Goal
by Zacks Equity Research
AnaptysBio's (ANAB) phase II study evaluating imsidolimab for treating moderate-to-severe acne, fails to show improvement over placebo in top-line primary or secondary endpoints. Shares down.
AnaptysBio, Inc. (ANAB) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
AnaptysBio, Inc. (ANAB) delivered earnings and revenue surprises of -149.56% and 99.42%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Scholar Rock Holding Corporation (SRRK) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Scholar Rock Holding Corporation (SRRK) delivered earnings and revenue surprises of 6.73% and 4.51%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
AnaptysBio, Inc. (ANAB) Earnings Expected to Grow: What to Know Ahead of Q4 Release
by Zacks Equity Research
AnaptysBio, Inc. (ANAB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Horizon (HZNP) Begins Enrollment in Rare Lung Disease Study
by Zacks Equity Research
Horizon (HZNP) enrolls the first patient in a phase IIb study evaluating HZN-825 for the treatment of idiopathic pulmonary fibrosis.
Amgen's (AMGN) KRAS Inhibitor Gets Nod in Japan for Lung Cancer
by Zacks Equity Research
Amgen's (AMGN) KRAS inhibitor, Lumakras, gets approval in Japan for the treatment of KRAS G12C-mutated positive advanced/recurrent non-small-cell lung cancer.
Zealand (ZEAL) Ends Enrollment in Short Bowel Syndrome Study
by Zacks Equity Research
Zealand Pharma (ZEAL) completes patient enrollment in the phase III EASE-SBS 1 study evaluating glepaglutide for the potential treatment of short bowel syndrome.
BioDelivery (BDSI) Stock Up on Raised Guidance for 2021
by Zacks Equity Research
BioDelivery Sciences International (BDSI) raises its financial guidance for full-year 2021. BDSI expects sales at the high end of its previous guidance.
CytomX (CTMX) Gets FDA Nod to Begin Study in Solid Tumors
by Zacks Equity Research
The FDA clears CytomX's (CTMX) investigational new drug application for CX-904, which is being developed for the treatment of advanced solid tumors.
Editas (EDIT) Focuses on Developing Gene-Editing Eye Drug
by Zacks Equity Research
Editas' (EDIT) lead pipeline candidate, EDIT-101, which employs CRISPR gene editing to treat LCA10, holds potential. Dependence on partners for collaboration revenues a woe.
Ascendis' (ASND) TransCon hGH Gets EU Nod for Pediatric GHD
by Zacks Equity Research
Ascendis Pharma (ASND) gets nod in Europe for TransCon hGH for the treatment of pediatric growth hormone deficiency.
Acadia (ACAD) Up More Than 20% in Past 3 Months: Here's Why
by Zacks Equity Research
Acadia's (ACAD) Nuplazid, approved for treating hallucinations and delusions associated with Parkinson's disease psychosis, has seen strong uptake so far. Its label expansion studies also hold promise.
Veru (VERU) Up on FDA's Fast Track Tag for Breast Cancer Drug
by Zacks Equity Research
The FDA bestows a Fast Track designation to Veru's (VERU) phase III program evaluating enobosarm for treating AR+ER+HER2- metastatic breast cancer. Shares rise.
Acadia (ACAD) Partners With Stoke for CNS Disorder Therapies
by Zacks Equity Research
Acadia (ACAD) signs a collaboration agreement with Stoke Therapeutics to develop/commercialize RNA-based medicines for addressing genetic neurodevelopmental diseases.
Horizon (HZNP) Submits sBLA for Krystexxa Label Expansion
by Zacks Equity Research
Horizon (HZNP) files a supplemental biologics license application to the FDA for Krystexxa plus methotrexate to treat people living with uncontrolled gout.
Amgen (AMGN) Inks Multi-Target Deal to Make Protein Therapeutics
by Zacks Equity Research
Amgen (AMGN) signs a collaboration agreement with Generate Biomedicines to develop protein therapeutics across several therapeutic areas and multiple modalities.
AnaptysBio, Inc. (ANAB) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
AnaptysBio, Inc. (ANAB) delivered earnings and revenue surprises of 67.57% and 150.54%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Glaxo's (GSK) Jemperli Gets FDA Approval for New Indication
by Zacks Equity Research
The FDA grants accelerated approval to Glaxo's (GSK) Jemperli for treating patients with mismatch repair-deficient recurrent/advanced solid tumors. This is the second approved indication for the drug.
AnaptysBio, Inc. (ANAB) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
AnaptysBio, Inc. (ANAB) delivered earnings and revenue surprises of 86.67% and 8.87%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
AnaptysBio, Inc. (ANAB) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
AnaptysBio, Inc. (ANAB) delivered earnings and revenue surprises of 7.04% and -1.45%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: AnaptysBio, Inc. (ANAB) Q1 Earnings Expected to Decline
by Zacks Equity Research
AnaptysBio, Inc. (ANAB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Glaxo (GSK) Gets FDA Nod for Endometrial Cancer Drug Jemperli
by Zacks Equity Research
The FDA grants accelerated approval to Glaxo's (GSK) Jemperli for treating women with recurrent or advanced dMMR endometrial cancer.